(1999). "A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.". J. Pharmacol. Exp. Ther. 290 (2): 635-40. PMID 10411572.v • d • eCytochro...
Jornil J, Nielsen TS, Rosendal I et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int, 226(1-3), e26-31 (2013)....
The CYP2C19 intermediate metabolizer and poor metabolizer (IM&PM) status was related to the raised risk of both MDD (OR = 1.547, P < 0.01) and BPD (OR = 1.808, P < 0.001). Conclusion Our data indicate that the impaired CYP2C19 metabolism caused by the haplotypes ...
Prolonged half‐life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction 来自 dx.doi.org 喜欢 0 阅读量: 29 摘要: No abstract is available for this article. 关键词: Humans Pyrimidines Aryl Hydrocarbon Hydroxylases ...
Allele Definition Table (1)): patients with an activity score of 0 are poor metabolizers (PMs), those with a score of 0.5 are considered intermediate metabolizers (IMs), and those with a score of 1.0, 1.5 or 2.0 represent normal metabolizers (NMs). Patients with a score >2.0 are ...
No subject carried the CYP2C9*2/*2, CYP2C9*3/*3, CYP2C19*17/*17, or CYP2C9*3/CYP2C19 genotype. The study is the first to describe the drug metabolizing enzyme polymorphisms, CYP2C9 and CYP2C19, in the Indonesian Buginese population.Ikawati...
No subject carried the CYP2C9*2/*2, CYP2C9*3/*3, CYP2C19*17/*17, or CYP2C9*3/CYP2C19*17 genotype. The study is the first to describe the drug metabolizing enzyme polymorphisms, CYP2C9 and CYP2C19, in the Indonesian Buginese population.Ikawati...
CYP2C9 and CYP2C19 are of interest as they exhibit wide inter-individual variation in expression, which influence the drug metabolism capacity. The CYP2C9 alleles of interest in this study were CYP2C9*2 and *3, and of CYP2C19 was CYP2C19. The study aimed to determine the frequencies of ...
It is worth noting that an individual carrying a non-functional allele such as CYP2C19*2, *3, or *4 will have impaired drug metabolism and is considered an intermediate metabolizer. In contrast, an individual carrying two non-functional alleles will be regarded as a poor metabolizer [25]. ...
The human cytochrome P450 (CYP) drug-metabolising enzymes (DMEs), such as CYP2D6, CYP2C9, CYP2C19, and CYP2B6, are subject to genetic polymorphism, which gives rise to individual genotypes with the correspondent genotype-predicted phenotypes classified in poor (gPM), intermediate (gIM), normal...